Key Points
- COO Christine Zedelmayer sold 11,900 shares of Equillium on Dec. 15 at an average price of $1.31 for $15,589, leaving her with 91,444 shares and representing an 11.51% reduction in her ownership.
- Zedelmayer has made multiple recent sales — 23,804 shares on Dec. 12 and 8,098 shares on Nov. 25 — totaling 43,802 shares sold in the past few weeks.
- Equillium trades near $1.22 with a market cap of about $74.3M, analysts have a consensus "Reduce" rating with a $1.00 target, and the company is a clinical‑stage biotech with lead candidate itolizumab in Phase III for acute graft‑versus‑host disease.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 11,900 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $1.31, for a total value of $15,589.00. Following the completion of the sale, the chief operating officer owned 91,444 shares of the company's stock, valued at approximately $119,791.64. This represents a 11.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Christine Zedelmayer also recently made the following trade(s):
- On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total value of $31,897.36.
- On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The stock was sold at an average price of $0.95, for a total value of $7,693.10.
Equillium Stock Performance
EQ stock opened at $1.22 on Tuesday. The firm has a market cap of $74.29 million, a P/E ratio of -1.97 and a beta of 1.92. Equillium, Inc. has a 1 year low of $0.27 and a 1 year high of $2.35. The stock has a 50-day simple moving average of $1.16 and a 200-day simple moving average of $1.00.
Equillium (NASDAQ:EQ - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08. On average, equities research analysts predict that Equillium, Inc. will post 0.14 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Equillium in a research note on Monday, December 8th. Wall Street Zen raised shares of Equillium from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $1.00.
Read Our Latest Stock Analysis on EQ
Institutional Trading of Equillium
A number of hedge funds have recently made changes to their positions in EQ. ADAR1 Capital Management LLC acquired a new stake in Equillium in the third quarter valued at $7,951,000. Woodline Partners LP bought a new stake in shares of Equillium in the 3rd quarter worth about $5,018,000. Vanguard Group Inc. raised its stake in shares of Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock valued at $1,879,000 after purchasing an additional 489,855 shares in the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of Equillium during the third quarter worth about $608,000. Finally, Aberdeen Group plc bought a new position in shares of Equillium during the third quarter worth about $543,000. Institutional investors and hedge funds own 27.05% of the company's stock.
Equillium Company Profile
(
Get Free Report)
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
